The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of 18FDG-PET CT in the management of invasive bladder cancer.
 
Pauline Bertolaso
No Relationships to Disclose
 
Véronique Brouste
No Relationships to Disclose
 
Anne Laure Cazeau
No Relationships to Disclose
 
Henri De Clermont-Gallerande
No Relationships to Disclose
 
Franck Bladou
No Relationships to Disclose
 
Mathilde Cabart
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Roche; Takeda
 
Alain Ravaud
Honoraria - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer; Roche
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; ipsen; MSD; Novartis; Pfizer; Roche
 
Marine Gross-Goupil
Consulting or Advisory Role - Amgen; Astellas Medivation; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); ipsen (Inst); Janssen-Cilag (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; ipsen; MSD Oncology; Roche; Roche; Roche